Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,895,424 papers from all fields of science
Search
Sign In
Create Free Account
refametinib
An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Narrower (1)
RDEA 119
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Chemical-biology approach to delineate the mechanism of action of HIV-1 latency reversing agents
Feng Qi Han
2017
Corpus ID: 51801902
Prostratin exhibits potent HIV-1 latency reversing activity, yet its molecular mechanism of action has not been defined in detail…
Expand
2017
2017
5PDThe acquired resistance to the combination of the anti-EGFR cetuximab and the MEK-inhibitor refametinib in KRAS mutated colorectal cancer cell lines depends on PI3K-signalling
P. Vitiello
,
G. Martini
,
+16 authors
E. Martinelli
2017
Corpus ID: 80572144
2016
2016
Targeted therapy in low-grade serous ovarian carcinoma : characterization of MEK inhibitor response in novel patient-derived cell lines
A. Dawson
2016
Corpus ID: 80312816
2016
2016
Abstract 2276: Sorafenib/Refametinib potently inhibits Wnt/β-catenin in vitro and patient-derived xenograft models of human hepatocellular carcinoma
H. Hung
,
R. Ong
,
+5 authors
K. Ziegelbauer
2016
Corpus ID: 78494914
2014
2014
Compositions pharmaceutiques contenant du réfamétinib
A. Stroyer
,
S. Skrabs
,
Michael Formell
,
Gabriele Winter
,
Rosemarie Kissenbeck
2014
Corpus ID: 194793918
La presente invention concerne des compositions pharmaceutiques contenant du refametinib, un hydrate, un solvate, un metabolite…
Expand
2014
2014
Cancer Therapy : Clinical APhase II Study of theEf fi cacy andSafety of theCombination Therapy of theMEK Inhibitor Refametinib ( BAY 86-9766 ) Plus Sorafenib for Asian Patients with Unresectable…
HoYeongLim
,
JeongHeo
,
+15 authors
W. Tak
2014
Corpus ID: 33643042
Purpose: There is an unmet need for treatment options in hepatocellular carcinoma (HCC). Sorafenib is currently the only approved…
Expand